Published in Proc Natl Acad Sci U S A on January 12, 2005
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63
Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol (2012) 5.19
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Tumours with PI3K activation are resistant to dietary restriction. Nature (2009) 3.60
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet (2012) 3.41
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet (2012) 3.13
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J (2007) 2.66
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget (2010) 2.44
DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol (2007) 2.38
Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer (2010) 2.35
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol (2006) 2.34
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A (2006) 2.23
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal (2008) 2.19
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med (2013) 1.98
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett (2010) 1.89
Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J (2009) 1.88
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res (2009) 1.64
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene (2010) 1.56
Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol (2011) 1.56
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Defining the blueprint of the cancer genome. Carcinogenesis (2008) 1.49
Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest (2013) 1.49
Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev (2009) 1.48
Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol (2009) 1.47
Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res (2009) 1.45
Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer (2008) 1.42
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am (2008) 1.41
Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol (2009) 1.37
PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol (2009) 1.36
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle (2008) 1.35
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets (2013) 1.33
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist (2011) 1.32
PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev (2009) 1.32
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol (2009) 1.29
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One (2010) 1.26
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer. Virology (2008) 1.20
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A (2014) 1.20
Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Res (2012) 1.19
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch (2011) 1.19
PI3Kα inhibitors that inhibit metastasis. Oncotarget (2010) 1.19
Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations. Curr Biol (2011) 1.18
The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol (2010) 1.16
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer (2009) 1.15
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res (2009) 1.15
Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer (2013) 1.15
Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival. Mol Cell Biol (2011) 1.14
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia (2012) 1.14
Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene (2009) 1.10
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med (2015) 1.09
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol (2006) 1.06
Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One (2012) 1.06
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer (2008) 1.05
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2012) 1.05
The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer (2010) 1.05
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch (2008) 1.05
Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem (2008) 1.04
BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3β signaling pathway. Cancer Res (2012) 1.01
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res (2015) 1.01
Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem (2013) 1.01
Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell (2007) 1.00
Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res (2013) 1.00
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res (2011) 0.98
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem (1999) 14.59
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell (1995) 11.86
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev (1999) 8.14
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A (1998) 8.03
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev (1998) 6.89
A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science (1991) 6.54
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet (1999) 6.18
Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J (1997) 5.57
PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 5.46
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
The mRNA 5' cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol (1998) 4.84
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res (2001) 4.63
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A (2001) 4.62
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol (2000) 4.24
Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res (1999) 4.04
Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem (2004) 4.01
Characteristics of two new avian tumor virus subgroups. Virology (1969) 3.81
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 3.73
TOR signaling. Sci STKE (2003) 3.61
PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol (2004) 3.57
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17
PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol (2001) 3.15
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A (2001) 3.01
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res (2001) 2.51
Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev (1990) 2.46
Formation of phosphatidylinositol 3-phosphate by isomerization from phosphatidylinositol 4-phosphate. Proc Natl Acad Sci U S A (1991) 2.35
The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem (2000) 1.71
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene (2002) 1.44
Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet (2000) 1.19
p70(S6K) controls selective mRNA translation during oocyte maturation and early embryogenesis in Xenopus laevis. Mol Cell Biol (1999) 1.14
Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int J Mol Med (2000) 1.07
Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Semin Oncol (2004) 0.92
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70
Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc Natl Acad Sci U S A (2003) 2.45
Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A (2004) 2.19
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc (2009) 1.72
Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67
Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res (2005) 1.59
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther (2011) 1.41
Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer (2009) 1.36
100 years of Rous sarcoma virus. J Exp Med (2011) 1.24
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol (2005) 1.20
A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20
Phosphorylation of AKT: a mutational analysis. Oncotarget (2011) 1.17
PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol (2010) 1.16
Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle (2005) 1.16
Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts. Oncogene (2003) 1.16
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle (2010) 1.11
Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett (2009) 1.11
Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A (2003) 1.09
Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology (2006) 1.07
Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc Natl Acad Sci U S A (2004) 1.01
Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A (2011) 0.98
Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem (2014) 0.96
MafA has strong cell transforming ability but is a weak transactivator. Oncogene (2003) 0.96
Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. Oncogene (2003) 0.96
Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep (2008) 0.95
An essential role for protein synthesis in oncogenic cellular transformation. Oncogene (2004) 0.94
Applying small RNA molecules to the directed treatment of human diseases: realizing the potential. Expert Opin Ther Targets (2008) 0.94
Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene (2002) 0.94
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation. J Am Chem Soc (2009) 0.93
Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions. J Am Chem Soc (2011) 0.93
TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther (2013) 0.92
Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. Mol Pharmacol (2009) 0.90
Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides. J Am Chem Soc (2004) 0.88
Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget (2010) 0.88
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells. Mol Ther Nucleic Acids (2013) 0.87
A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol (2006) 0.87
Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. Int J Cancer (2009) 0.87
Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res (2009) 0.86
Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. Int J Cancer (2010) 0.84
PI 3-kinases: hidden potentials revealed. Cell Cycle (2006) 0.84
Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle (2011) 0.83
Progress in breast cancer research. Proc Natl Acad Sci U S A (2012) 0.82
Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle (2011) 0.81
Biochemical and biological characterization of tumor-associated mutations of p110alpha. Methods Enzymol (2008) 0.81
Cell entry by non-enveloped viruses. Curr Top Microbiol Immunol (2010) 0.81
Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. Oncogene (2003) 0.80
The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression. Oncogene (2003) 0.80
MYCNOS functions as an antisense RNA regulating MYCN. RNA Biol (2015) 0.79
Jun: stealth, stability, and transformation. Mol Cell (2005) 0.78
v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene (2004) 0.77
The classic: integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts: (RNA tumor viruses/reassociation kinetics/duck cells). 1973. Clin Orthop Relat Res (2008) 0.75
RICHARD BING: 12 OCTOBER 1909 - 8 NOVEMBER 2010. Proc Am Philos Soc (2014) 0.75
A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic. Methods Mol Biol (2015) 0.75
TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motif. Virology (2008) 0.75